Overview

A Study of Mosliciguat in PH-ILD

Status:
RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Phase:

PHASE2

Details

Lead Sponsor:

Pulmovant, Inc.

Treatments:

Dry Powder Inhalers